IIT-DHAKAL-VICD-MM
Phase II
OPEN TO ACCRUAL
A Multisite, Phase II Study of Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone (VICD) Induction in Transplant-Eligible Multiple Myeloma Patients with Renal Insufficiency
UAB-21107-MASTER-2-MM
Phase II
OPEN TO ACCRUAL
MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma - Master-2 Trial